Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer

Progression of Pancreatic Adenocarcinoma Is Significantly Impeded with a Combination of Vaccine and COX-2 Inhibition

(2014) P. Mukherjee et al.   JOURNAL OF IMMUNOLOGY

Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case–control study

(2010) M C Bradley et al.   BRITISH JOURNAL OF CANCER

The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth

(2010) Yin-Hsun Feng et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF

(2010) M E Behrens et al.   ONCOGENE

Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma

(2009) Fei Zhao et al.   IMMUNOLOGY

Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice

(2009) Hanh K. Le et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer

(2009) J M Bailey et al.   ONCOGENE

Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes

(2008) Sudarshan K. Vijay et al.   ACTA DIABETOLOGICA

Rosiglitazone and Risk of Cancer: A meta-analysis of randomized clinical trials

(2008) M. Monami et al.   DIABETES CARE

Toll-like receptor 4 mediates cross-talk between peroxisome proliferator-activated receptor γ and nuclear factor-κB in macrophages

(2008) Brian M. Necela et al.   IMMUNOLOGY

Phosphorylation of MUC1 by Met Modulates Interaction with p53 and MMP1 Expression

(2008) Pankaj K. Singh et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Immune Tolerance of Cancer is Mediated by IDO That is Inhibited by COX-2 Inhibitors Through Regulatory T Cells

(2008) Sung Yong Lee et al.   JOURNAL OF IMMUNOTHERAPY

Effect of Celecoxib and the Novel Anti-Cancer Agent, Dimethylamino-Parthenolide, in a Developmental Model of Pancreatic Cancer

(2008) Michele T. Yip-Schneider et al.   PANCREAS